Equine Sports Council

Controlled Medications Library

ESC MEDICATION CLASSIFICATIONClass A - Therapeutic

ESC Medication Library · Revision 3

← Medication library · Compare sanctioning bodies

Betamethasone,
Betavet

Medication Facts

Performance enhancing
Potentially
Total hours to clear
504
Frequently used
Most Prescribed
ESC ID
BETAME-0118
Trade names
Betavet
Drug type
Corticosteroid
Plasma half-life · hours
9
Equine dosing
9 mg or 1.5 mL per joint, **Joint Injections** **Due to severe contraindictations consult a licensed veterinarian to discuss treatment options before combining with Betamethasone, Dexamethasone, Methylprednisolne, Isoflupredone, Triamcinolone. If switching between these withdrawals must be at least 7 days,
Cmax · peak plasma concentration
2.70 to 3.97 ng/mL
Tmax · time to peak plasma concentration
4 to 8 hours
ESC concentration guidance
12 HRS WD 6500 pg/mL IA, 6000 pg/mL IM. 72 hrs WD 10 pg/mL IA, 100 pg/mL IM
Primary withdrawal · hours
12
Washout withdrawal · hours
168
ESC control type
A1 - Generally Controlled - Therapeutic
Medication report required
Generally not required, however understand exceptions.

Uses & side effects

Drug interactions

Because BetaVet contains a highly potent corticosteroid (betamethasone), its rapid systemic absorption following an intra-articular hock injection can cause severe, adverse reactions if combined with specific medications.The primary equine drug interactions for betamethasone are detailed below.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)Examples: Phenylbutazone (Bute), Flunixin meglumine (Banamine), Firocoxib (Equioxx), Ketoprofen.Interaction: Betamethasone and NSAIDs both interfere with the protective prostaglandin pathways that maintain the stomach lining and ensure adequate blood flow to the kidneys.Clinical Impact: High. Concurrent use multiplies the risk of severe gastrointestinal ulceration, right dorsal colitis, and acute kidney injury. Systemic NSAIDs should be withheld for several days following a BetaVet injection.2. Other CorticosteroidsExamples: Dexamethasone, Triamcinolone acetonide (Vetalog), Methylprednisolone acetate (Depo-Medrol).Interaction: Stacking multiple synthetic steroids creates an additive effect that overloads the horse's metabolic and endocrine systems.Clinical Impact: High. This combination massively extends the duration of hypothalamic-pituitary-adrenal (HPA) axis suppression and drastically increases the risk of life-threatening corticosteroid-associated laminitis.3. Macrolide Antibiotics & Azole Antifungals (CYP450 Inhibitors)Examples: Erythromycin, Clarithromycin, Rifampin (often used together for Rhodococcus equi), Ketoconazole.Interaction: Betamethasone is metabolized in the liver by cytochrome P450 enzymes. Macrolides and azoles act as potent inhibitors of these enzymes, shutting down the liver's ability to clear the steroid.Clinical Impact: Moderate to High. Concurrent use slows down systemic clearance, extending the plasma half-life of betamethasone well past its standard 8 hours. This triggers prolonged adrenal suppression and unpredictable drug testing windows.4. Loop DiureticsExamples: Furosemide (Salix/Lasix).Interaction: Corticosteroids promote potassium excretion in the kidneys. Loop diuretics also aggressively flush potassium from the body.Clinical Impact: Moderate. When used together, they can induce severe hypokalemia (dangerously low blood potassium levels), resulting in skeletal muscle weakness and cardiac arrhythmias. This is highly relevant if a racing horse receives race-day furosemide close to a BetaVet treatment window.5. Vaccines and Modified-Live BiologicsInteraction: The rapid initial plasma spike of BetaVet causes a brief but intense suppression of the horse's immune cell response.Clinical Impact: Moderate. Administering routine vaccines (e.g., Tetanus, West Nile, EEE/WEE) within days of a BetaVet injection will blunt the horse's ability to build adequate protective antibodies, rendering the vaccine ineffective.6. Insulin and Metabolic Support MedicationsExamples: Exogenous Insulin, Pergolide mesylate (Prascend).Interaction: Betamethasone directly opposes the actions of insulin, triggering transient insulin resistance, hyperinsulinemia, and hyperglycemia.Clinical Impact: High for Equine Metabolic Syndrome (EMS) or Pituitary Pars Intermedia Dysfunction (PPID/Cushing's) patients. BetaVet will actively counteract these daily medications, spiking insulin levels and immediately threatening to precipitate a laminitic episode.

Contraindications

Betamethasone, Dexamethasone, Methylprednisolne, Isoflupredone, Triamcinolone.

Government Numbers

BetaVet betamethasone sodium phosphate / acetate suspension, 6 mg/mL: NADA 141-418; NDC 10797-720-01 (5 mL vial). Labeler: American Regent, Inc. Intra-articular use in horses; not for IV use. These identifiers apply to BetaVet suspension. Reviewed September 18, 2026. Full label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3eb6b1d3-4485-4b25-aaab-92de9b2fb322

Sanctioning-body comparison

Plasma only. Compare published competition guidance for this medication. ESC guidance remains in Medication Facts above. A dosing guideline, withdrawal recommendation and laboratory detection threshold are different measures.

Sources reviewed September 23, 2026. “Not verified” means a gap in this comparison, not zero tolerance or permission. Doses describe the cited rules; your veterinarian must determine treatment and withdrawal.

Published guidance by organization
OrganizationPublished dose & routePlasma concentrationWithdrawal / timingControl / penalty class
AQHA Show HorsesShow rules · 2026 handbook
Conditions & sources

An unverified entry is not permission to use this medication. Consult the linked current rules.

Reviewed 2026-09-23

Not verified for this medication.Not verified for this medication.Not verified for this medication.Medication-specific control not yet verified.
APHA Paint Show HorsesShow rules · 2026 Rule Book
Conditions & sources

An unverified entry is not permission to use this medication. Consult the linked current rules.

Reviewed 2026-09-23

Not verified for this medication.Not verified for this medication.Not verified for this medication.Medication-specific control not yet verified.
ARCI Model RulesRacing model · Rules 15 / UCG 20.0 / CTMS 4.2.1
Conditions & sources

These numeric limits and times do not apply to flat/jump racing. ARCI’s flat/jump rules impose a 14-day intra-articular stand-down and prohibit corticosteroid stacking. ARCI model comparison only; no state-specific rule is substituted. Schedule timing is tied to its stated regimen and is not a clearance guarantee.

CTMS 4.2.1 corticosteroid note; ARCI-011-020(F); UCG 20.0 PDF p. 16

Reviewed 2026-09-23

9 mg specified sodium phosphate/acetate formulation intra-articular — harness only10 pg/mL — harness only7 days — harness onlyDrug Class 4 · Penalty Class C. Harness-only CTMS threshold and timing.
USEFNational Therapeutic Substance Provisions · 2026 + July amendment
Conditions & sources

An unverified entry is not permission to use this medication. Consult the linked current rules.

Reviewed 2026-09-23

Not verified for this medication.Not verified for this medication.Not verified for this medication.Medication-specific control not yet verified.